We have provided sell-side transaction support on the sale of DYCONEX AG (DYCONEX), a Swiss company specialising in high-reliability printed circuit boards (PCB) for medical and other advanced applications, to SOMACIS, a portfolio company of Bain Capital and Chequers Capital.
Founded in 1964 and headquartered in Bassersdorf, Switzerland, DYCONEX is a premier manufacturer of highly miniaturised and customised PCBs as well as interconnect solutions, primarily serving the medtech sector. The company produces high-reliability, IPC Class III PCBs for medical applications, including hearing aids, pacemakers, defibrillators, cochlear implants, and imaging equipment. The company employs approximately 200 highly skilled professionals and operates from a cutting-edge facility equipped with advanced machinery and cleanroom spaces.
This transaction strengthens SOMACIS’ position as a leading global player in the high-tech PCB industry, expanding its technological capabilities and market reach. DYCONEX’s cutting-edge expertise, particularly in flexible, rigid-flex, and ultra-thin PCB solutions, will enhance SOMACIS’ product portfolio, enabling the company to deliver even more innovative solutions to its customers worldwide.
Based in Italy and backed by Bain Capital and Chequers Capital, SOMACIS is a global provider of high-tech PCBs with a strong presence in the aerospace, defence, and medical industries. Chequers Capital, the former majority owner of SOMACIS, retains a minority shareholding in the company after Bain Capital acquired the controlling shares of SOMACIS.
